{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:49:21Z","timestamp":1761176961698,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.tracli.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T12:58:49Z","timestamp":1617886729000},"page":"321-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis"],"prefix":"10.1016","volume":"28","author":[{"given":"J.","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"World Health Organization","key":"10.1016\/j.tracli.2021.03.004_bib0210"},{"key":"10.1016\/j.tracli.2021.03.004_bib0215","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.03.004_bib0220","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","article-title":"Middle East respiratory syndrome","volume":"395","author":"Memish","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2021.03.004_bib0225","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1473-3099(20)30195-X","article-title":"Real estimates of mortality following COVID-19 infection","volume":"20","author":"Baud","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tracli.2021.03.004_bib0230","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u00a0\u2013\u00a0Preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.03.004_bib0235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijid.2020.03.013","article-title":"Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression","volume":"95","author":"Liu","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tracli.2021.03.004_bib0240","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"10236","key":"10.1016\/j.tracli.2021.03.004_bib0245","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.tracli.2021.03.004_bib0250","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.03.004_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tracli.2021.03.004_bib0260","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tracli.2021.03.004_bib0265","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"year":"2014","series-title":"Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks","author":"WHO","key":"10.1016\/j.tracli.2021.03.004_bib0270"},{"key":"10.1016\/j.tracli.2021.03.004_bib0275","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tracli.2021.03.004_bib0280","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.tracli.2021.03.004_bib0285","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.tracli.2021.03.004_bib0290","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jinf.2016.11.009","article-title":"Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone","volume":"74","author":"Sahr","year":"2017","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.tracli.2021.03.004_bib0295","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","article-title":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","volume":"5","author":"Beigel","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.tracli.2021.03.004_bib0300","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.tracli.2021.03.004_bib0305","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"year":"2012","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","key":"10.1016\/j.tracli.2021.03.004_bib0310"},{"key":"10.1016\/j.tracli.2021.03.004_bib0315","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.tracli.2021.03.004_bib0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for ebola virus disease in guinea","volume":"374","author":"Van Griensven","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.tracli.2021.03.004_bib0325","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial","volume":"7","author":"Davey","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.tracli.2021.03.004_bib0330","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3947\/ic.2016.48.2.118","article-title":"Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea","volume":"48","author":"Choi","year":"2016","journal-title":"Infect Chemother"},{"issue":"2","key":"10.1016\/j.tracli.2021.03.004_bib0335","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.tracli.2021.03.004_bib0340","first-page":"447","article-title":"Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1)","volume":"16","author":"Chan","year":"2010","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.tracli.2021.03.004_bib0345","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jama.1919.26110010013009d","article-title":"Treatment of influenzal pneumonia with plasma of convalescent patients","volume":"72","author":"O\u2019Malley","year":"1919","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tracli.2021.03.004_bib0350","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jama.1919.02610020020007","article-title":"Serum treatment of postinfluenzal bronchopneumonia","volume":"72","author":"Kahn","year":"1919","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tracli.2021.03.004_bib0355","first-page":"666","article-title":"Human serum in the treatment of influenza bronchopneumonia","volume":"109","author":"Gould","year":"1919","journal-title":"N Y Med J"},{"issue":"11","key":"10.1016\/j.tracli.2021.03.004_bib0360","doi-asserted-by":"crossref","first-page":"30199","DOI":"10.1016\/S2213-2600(19)30199-7","article-title":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial","volume":"7","author":"Beigel","year":"2019","journal-title":"Lancet Respir Med"},{"year":"2016","series-title":"MERS-CoV: clinical decision making support for treatment","author":"England","key":"10.1016\/j.tracli.2021.03.004_bib0365"},{"key":"10.1016\/j.tracli.2021.03.004_bib0370","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiv304","article-title":"The contribution of Ebola viral load at admission and other patient characteristics to mortality in a M\u00e9decins Sans Fronti\u00e8res Ebola Case Management Centre, Kailahun, Sierra Leone, June-October 2014","volume":"212","author":"Fitzpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tracli.2021.03.004_bib0375","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/650581","article-title":"Delayed decrease of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection","volume":"50","author":"To","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tracli.2021.03.004_bib0380","article-title":"Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome","author":"Yang","year":"2020","journal-title":"medRxiv"},{"issue":"Suppl. 1","key":"10.1016\/j.tracli.2021.03.004_bib0385","first-page":"65S","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"issue":"20","key":"10.1016\/j.tracli.2021.03.004_bib0390","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1128\/JVI.00671-11","article-title":"Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway","volume":"85","author":"Jaume","year":"2011","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.tracli.2021.03.004_bib0395","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.tracli.2021.03.004_bib0400","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.tracli.2021.03.004_bib0405","first-page":"830","article-title":"The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study","volume":"61","author":"Duan","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.tracli.2021.03.004_bib0410","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:39:44Z","timestamp":1761129584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782021000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1246782021000422"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2021.03.004","relation":{},"ISSN":["1246-7820"],"issn-type":[{"type":"print","value":"1246-7820"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}